Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00973739
Other study ID # 09-0328
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received September 3, 2009
Last updated October 18, 2012
Start date September 2009
Est. completion date December 2012

Study information

Verified date October 2012
Source New York University School of Medicine
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous system. It causes non-cancerous tumors (which are known as neuromas) to grow on the nerves around a person's body. Some signs of NF2 include a gradual loss of hearing and tumors growing on the skin, the brain and the spinal cord which can lead to complications.

Lapatinib is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors. The investigators know a lot about how well it is tolerated, but the investigators do not know if it is effective in treating your condition, therefore it is considered to be an investigational medication. This study will test whether Lapatinib may shrink tumors commonly found in patients with NF2 or stop them from growing. This will help us to decide if Lapatinib should be used to treat NF2 patients in future. Lapatinib is a drug that has been used for over 10 years to treat various forms of cancer. It has not been studied for the treatment of tumors in NF2 patients.


Description:

In this trial, we propose to assess the objective response rates to Lapatinib in patients with NF2-related tumors. Lapatinib is a commercially available inhibitor of ErbB2 and EGF. Data suggests that abnormal signaling via EGFR and ErbB2 is a major contributor to tumor growth and progression in both sporadic and NF2-related VS and that inhibition of this signaling pathway can result in decreased tumor growth.

Demonstrating that Lapatinib produces an objective response to reduce tumor volume or stabilize disease will provide additional treatment options for NF patients with multiple tumor growth. For patients with VS we expect to see ≥ 10 dB improvement in PTA and/or improvement in SDS, compared to the audiogram at initiation of treatment. Currently there are no available treatment options for NF2 patients with multiple tumors. Depending on tumor cell type, lapatinib has cytostatic or cytotoxic antitumor effects, and in a recent study assessing the biological effects of Lapatinib on the associated molecular pathways and tumor growth in patients with solid tumors, a correlation was seen between tumor response and pre-treatment levels of (phosphor)-ErbB2 and (phosphor)-ERK1/2.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 17
Est. completion date December 2012
Est. primary completion date October 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 4 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patients must be at least 4 years of age.

2. Patients must meet diagnostic criteria for NF2 and at least one volumetrically measured NF2-related brain or spinal tumor with radiographic evidence of progression over the past 12 months, designated as the primary target OR volumetrically measurable VS with ipsilateral progressive hearing loss over the past 12 months, designated as the primary target tumor.

3. Significant hearing loss criteria for enrollment.

4. Karnofsky (PS) OR Lansky 50-100% (>16 years of age)

5. Absolute neutrophil count = 1,000/mm3 g/dL

6. Hemoglobin = 8 g/dL

7. Creatinine = 1.5 times upper limit of normal (ULN) OR corrected glomerular filtration rate = 70 ml/min

8. Bilirubin = 1.5 times ULN

9. ALT = 2.5 times ULN

10. Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy.

11. Steroids are allowed for progressive symptoms but patient must be on a stable dose for at least 1 week prior to study entry.

12. Any neurologic deficits must be stable for = 1 week.

13. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus.

14. Normal cardiac left ventricular ejection fraction (LVEF) by transthoracic echocardiogram.

15. Able to provide written informed consent (or consent by parent/legal guardian for minors)

Exclusion Criteria:

1. Patients with serious concurrent infection or medical illness.

2. Neurological deficits that are rapidly progressing.

3. Patients who are pregnant or breast-feeding.

4. Anti-tumor therapy within 4 weeks prior to enrollment.

5. Radiation therapy within 2 months prior to enrollment.

6. Prior therapy with agents targeting EGFR or ErbB2.

7. Any surgery within 4 weeks prior to enrollment.

8. Significant gastrointestinal disorder(s)

9. Known cardiac disease

10. Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Patients who have been free of disease (any prior malignancy) for more than five years are eligible for this study.

11. Patients cannot have received cytochrome P450-inducing anticonvulsants (EIADs; e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents (e.g., rifampin) or P450-inhibiting agents (Ketoconazole, Itraconazole, Clarithromycin, Atazanavir, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Lapatinib
Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment. Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily) Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily) Duration: Up to 12 months, depending on treatment response.

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
New York University School of Medicine GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To estimate the objective response rates to Lapatinib in patients with NF2-related tumors including cranial nerve schwannomas, meningiomas and ependymomas. Every three months for one year No
Secondary To assess the toxicity of Lapatinib given daily in patients with NF2. Monthly for one year Yes
Secondary To examine the association of objective measures of response on MRI, i.e. volumetric tumor analysis and perfusion with clinical measures of response, i.e. audiogram in patients with vestibular schwannomas (VS). Every three months for one year No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Recruiting NCT03593577 - Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
Completed NCT03210285 - WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data